In Silico Study of Five SARS CoV-2 Target Proteins on Known Drugs In silico study of five SARS CoV-2 target proteins
Iranian Journal of Pharmaceutical Sciences,
Vol. 17 No. 2 (2021),
1 April 2021
,
Page 87-104
https://doi.org/10.22037/ijps.v17.40288
Abstract
COVID-19 is an infectious disease that started at the end of 2019 in China then became pandemic worldwide. A number of crystal structures of coronavirus proteins are available in the Protein Data Bank. In this paper, we reported results from the virtual screening of databases including 2701 FDA approved drugs against five known coronavirus protein targets. Our results showed a wide range of scores for different drugs of which some were predicted to be active against one or some of the proteins. Among all of the compounds with higher scores, tannic acid and cobicistat showed to be active against four and two of the studied proteins respectively. Tannic acid which was reported to be an antiviral and potent inhibitor of hepatitis C virus activity and cobicistat with anti- HIV activity might be useful for the cure of COVID-19. According to the results, we suggest more studies on these valuable potential drugs.
- Virtual screening
- Coronavirus
- Tannic acid
- Cobicistat
- COVID-19
- SARS CoV-2
How to Cite
References
[2] de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RA, Galiano M, Gorbalenya AE and Memish ZA. Commentary: Middle east respiratory syndrome coronavirus (mers-cov): announcement of the coronavirus study group. J. Virol. (2013) 87: 7790-92.
[3] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W and Lu R. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. (2020) 382: 727-33.
[4] Ji W, Wang W, Zhao X, Zai J and Li X. Cross‐species transmission of the newly identified coronavirus 2019‐nCoV. J. Med. Virol. (2020) 92: 433-40.
[5] Hulswit R, De Haan C and Bosch B-J, Coronavirus spike protein and tropism changes, In: Smith K and Lauffer M (Eds.) Adv. Virus Res. Elsevier, New York (2016) 29-57.
[6] Vijay R and Perlman S. Middle East respiratory syndrome and severe acute respiratory syndrome. Curr. Opin. Virol. (2016) 16: 70-76.
[7] Lai C-C, Shih T-P, Ko W-C, Tang H-J and Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int. J. Antimicrob. Agents (2020) 55: 105924.
[8] Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, Liu W, Bi Y and Gao GF. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. (2016) 24: 490-502.
[9] Jiang S, Xia S, Ying T and Lu L. A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. Cell. Mol. Immunol. (2020) 17: 554-54.
[10] Woo PC, Lau SK, Lam CS, Tsang AK, Hui S-W, Fan RY, Martelli P and Yuen K-Y. Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in Gammacoronavirus. J. Virol. (2014) 88: 1318-31.
[11] Wold WS and Ison MG, Adenovirus, In: Knipe D and Howley P (Eds.) Fields Virology 6ed. Lippincott, Williams & Wilkins, New York (2013) 1732-67.
[12] Enjuanes L, Gorbalenya A, De Groot R, Cowley J, Ziebuhr J and Snijder E, Nidovirales, In: Mahy B and Van Regenmortel M (Eds.) Encyclopedia of virology, 3rd ed, Washigton (2008) 419-22.
[13] Almeida J, Berry D, Cunningham C, Hamre D, Hofstad M, Mallucci L, McIntosh K and Tyrrell D. Coronaviruses. Nature (1968) 220: 2-5.
[14] Kuypers J, Martin ET, Heugel J, Wright N, Morrow R and Englund JA. Clinical disease in children associated with newly described coronavirus subtypes. Pediatrics (2007) 119: 70-76.
[15] van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, Osterhaus AD, Haagmans BL, Gorbalenya AE and Snijder EJJM. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio (2012) 3: 1-9.
[16] Leong H-N, Chan K-P, Le Oon L, Koay ES, Ng L-C, Lee M-A, Barkham T, Chen MI, Heng B-H and Ling A-E. Clinical and laboratory findings of SARS in Singapore. Ann. Acad. Med. Singapore (2006) 35: 332-25.
[17] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z and Xiong Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA (2020) 323: 1061-69.
[18] Wege H and Ter Meulen V, The structure and replication of coronaviruses, In: Spaeth M (Ed.) Curr. Top. Microbiol. Immunol. Springer, New York City (1982) 131-63.
[19] Harris C, Carson G, Baillie JK, Horby P and Nair H. An evidence-based framework for priority clinical research questions for COVID-19. J. Glob. Health (2020) 10: 1-10.
[20] Maruta H and He H. PAK1-blockers: Potential Therapeutics against COVID-19. Medicine in Drug Discovery (2020) 6: 1-7.
[21] Liao J, Way G and Madahar V. Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies. Medicine in Drug Discovery (2020) 5: 1-5.
[22] Chou K-C, Wei D-Q and Zhong W-Z. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem. Biophys. Res. Commun. (2003) 308: 148-51.
[23] Yu R, Chen L, Lan R, Shen R and Li P. Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. Int. J. Antimicrob. Agents (2020) 56: 1-5.
[24] Nejabat M, Kahe H, Shirani K, Ghorbannejad P, Hadizadeh F and Karimi G. Health risk assessment of heavy metals via dietary intake of wheat in Golestan Province, Iran. Hum. Ecol. Risk Assess. (2017) 23: 1193-201.
[25] Cava C, Bertoli G and Castiglioni I. In silico discovery of candidate drugs against Covid-19. Viruses (2020) 12: 404.
[26] Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. (2020) 248: 117477.
[27] Elmezayen AD, Al-Obaidi A, Şahin AT and Yelekçi K. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes. J. Biomol. Struct. Dyn. (2020): 1-13.
[28] Barros RO, Junior FL, Pereira WS, Oliveira NM and Ramos RM. Interaction of drug candidates with various SARS-CoV-2 receptors: An in silico study to combat COVID-19. J. Proteome Res. (2020).
[29] Shah B, Modi P and Sagar SR. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach. Life Sci. (2020) 252: 117652.
[30] Abdelli I, Hassani F, Bekkel Brikci S and Ghalem S. In silico study the inhibition of Angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from western Algeria. J. Biomol. Struct. Dyn. (2020): 1-17.
[31] Pandey P, Rane JS, Chatterjee A, Kumar A, Khan R, Prakash A and Ray S. Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development. J. Biomol. Struct. Dyn. (2020): 1-11.
[32] Rabby MII. Current drugs with potential for treatment of COVID-19: a literature review. J. Pharm. Pharm. Sci. (2020) 23: 58-64.
[33] F Z, R W and IM R. Treatment of Central Diabetes Insipidus in Adults and Children With Desmopressin: A Synthetic Analogue of Vasopressin. Arch Intern Med (1978) 138: 1382–85.
[34] Hewison C, Ferlazzo G, Avaliani Z, Hayrapetyan A, Jonckheere S, Khaidarkhanova Z, Mohr E, Sinha A, Skrahina A and Vambe D. Six-month response to delamanid treatment in MDR TB patients. Emerg. Infect. Dis. (2017) 23: 1746-48.
[35] Liu S, Chen R and Hagedorn CH. Tannic acid inhibits hepatitis C virus entry into Huh7. 5 cells. PLoS One (2015) 10: e0131358.
[36] Lin L-T, Chen T-Y, Chung C-Y, Noyce RS, Grindley TB, McCormick C, Lin T-C, Wang G-H, Lin C-C and Richardson CD. Hydrolyzable tannins (chebulagic acid and punicalagin) target viral glycoprotein-glycosaminoglycan interactions to inhibit herpes simplex virus 1 entry and cell-to-cell spread. J. Virol. (2011) 85: 4386-98.
[37] Orlowski P, Tomaszewska E, Gniadek M, Baska P, Nowakowska J, Sokolowska J, Nowak Z, Donten M, Celichowski G and Grobelny J. Tannic acid modified silver nanoparticles show antiviral activity in herpes simplex virus type 2 infection. PLoS One (2014) 9: e104113.
[38] Khan NS, Ahmad A and Hadi S. Anti-oxidant, pro-oxidant properties of tannic acid and its binding to DNA. Chem. Biol. Interact. (2000) 125: 177-89.
[39] Scalbert A. Antimicrobial properties of tannins. Phytochemistry (1991) 30: 3875-83.
[40] Fukuchi K, Sakagami H, Okuda T, Hatano T, Tanuma S-i, Kitajima K, Inoue Y, Inoue S, Ichikawa S and Nonoyama M. Inhibition of herpes simplex virus infection by tannins and related compounds. Antiviral Res. (1989) 11: 285-97.
[41] Chung KT, Jr SS, Lin WF and Wei C. Growth inhibition of selected food‐borne bacteria by tannic acid, propyl gallate and related compounds. Lett. Appl. Microbiol. (1993) 17: 29-32.
[42] Horikawa K, Mohri T, Tanaka Y and Tokiwa H. Moderate inhibition of mutagenicity and carcinogenicity of benzo [a] pyrene, 1, 6-dinitropyrene and 3, 9-dinitrofluoranthene by Chinese medicinal herbs. Mutagenesis (1994) 9: 523-26.
[43] Vilhelmova-Ilieva N, Galabov AS and Mileva M, Tannins as Antiviral Agents, In: Aires A (Ed.) Tannins-Structural Properties, Biological Properties and Current Knowledge. IntechOpen, London (2019) 1-13.
[44] Schimanski CC, Schwald S, Simiantonaki N, Jayasinghe C, Gönner U, Wilsberg V, Junginger T, Berger MR, Galle PR and Moehler M. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin. Cancer Res. (2005) 11: 1743-50.
[45] Peters CA and Walsh PC. The effect of nafarelin acetate, a luteinizing-hormone–releasing hormone agonist, on benign prostatic hyperplasia. N. Engl. J. Med. (1987) 317: 599-604.
[46] Tally FP and DeBruin MF. Development of daptomycin for gram-positive infections. J. Antimicrob. Chemother. (2000) 46: 523-26.
[47] Mathias A, German P, Murray B, Wei L, Jain A, West S, Warren D, Hui J and Kearney B. Pharmacokinetics and pharmacodynamics of GS‐9350: a novel pharmacokinetic enhancer without anti‐HIV activity. Clin. Pharmacol. Ther. (2010) 87: 322-29.
[48] Ndongo‐Thiam N, Berthillon P, Errazuriz E, Bordes I, De Sequeira S, Trépo C and Petit MA. Long‐term propagation of serum hepatitis C virus (HCV) with production of enveloped HCV particles in human HepaRG hepatocytes. Hepatology (2011) 54: 406-17.
[49] Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki J-P, Lester L and Sievert W. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet (2015) 385: 1075-86.
[50] Beibei L, Yun C, Mengli C, Nan B, Xuhong Y and Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int. J. Antimicrob. Agents (2010) 35: 3-12.
[51] Kam P, Williams S and Yoong F. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia (2004) 59: 993-1001.
[52] Sacco E, Bientinesi R, Tienforti D, Racioppi M, Gulino G, D'Agostino D, Vittori M and Bassi P. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin. Drug Discov. (2014) 9: 433-48.
[53] Reviriego C. ASUNAPREVIR HCV Serine Protease NS3 Inhibitor Treatment of Hepatitis C Virus. Drug Future (2012) 37: 247-54.
[54] Sarpal DK, Robinson DG, Lencz T, Argyelan M, Ikuta T, Karlsgodt K, Gallego JA, Kane JM, Szeszko PR and Malhotra AK. Antipsychotic treatment and functional connectivity of the striatum in first-episode schizophrenia. JAMA psychiatry (2015) 72: 5-13.
[55] Russell A and Day M. Antibacterial activity of chlorhexidine. J. Hosp. Infect. (1993) 25: 229-38.
[56] Åkerlund M, Carlsson A, Melin P and Trojnar J. The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin. Acta Obstet. Gynecol. Scand. (1985) 64: 499-504.
[57] Manal H and Tolba AM. Effect of Loratadine on the Renal Cortex of Mother and Offspring of Albino Rats. J. Am. Sci. (2014) 9: 81-89.
[58] Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR and Horban A. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. (2011) 364: 2417-28.
- Abstract Viewed: 87 times
- IJPS_Volume 17_Issue 2_Pages 87-104 Downloaded: 35 times